GlassScriptPhysician profile
Andrew Gardner
NPI 1427209857
$536.96
in general payments reported to CMS, 2019-2025
11 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.10 · 2022: $23.64 · 2023: $96.86 · 2024: $134 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $223.34 | 2023-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $82.25 | 2021-2023 | |
| Tris Pharma INC | $49.88 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Merck Sharp & Dohme LLC | $40.92 | 2021 | |
| Glaxosmithkline, LLC. | $26.67 | 2021-2024 | Pediarix, Bexsero |
| Corium, LLC | $22.88 | 2025 | Azstarys |
| Organon LLC | $22.20 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $21.01 | 2025 | |
| Noven Therapeutics, LLC | $17.91 | 2025 | Xelstrym |
| Seqirus USA INC | $16.21 | 2025 | Flucelvax |
| Cumberland Pharmaceuticals, INC. | $13.69 | 2024 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.